Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Boomsma, F ; Pedersen-Bjergaard, U ; Agerholm-Larsen, Birgit ; Hut, H ; Dhamrait, Sukhbir S. ; Thorsteinsson, B ; van den Meiracker, Anton H. / Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus. In: Diabetologia. 2005 ; Vol. 48, No. 5. pp. 1002-7.

Bibtex

@article{24b5ff790bc7412bb2ed2d6f3c815d08,
title = "Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus",
abstract = "AIMS/HYPOTHESIS: Plasma semicarbazide-sensitive amine oxidase (SSAO) is elevated in patients with type 1 and type 2 diabetes and has been implicated in the pathophysiology of diabetic late complications. The regulation of SSAO production remains unknown. We studied correlations between plasma SSAO activity and parameters associated with diabetic late complications.METHODS: Plasma SSAO was measured in a well-characterised group of 287 patients with type 1 diabetes. Standard statistical methods were used to investigate correlations with clinical parameters and components of the renin-angiotensin system.RESULTS: Overall, plasma SSAO was elevated, at 693+/-196 mU/l (mean+/-SD; normal controls 352+/-102 mU/l). Plasma SSAO was higher in the group with late complications or hypertension, and in patients treated with ACE-inhibitors. In univariate analysis a significant positive correlation (p<0.001, r=0.27) was found between plasma SSAO and serum ACE activity in patients untreated with ACE inhibitors or angiotensin II receptor antagonists (n=221), but plasma SSAO did not differ by ACE I/D genotype. Plasma SSAO correlated positively with duration of diabetes, HbA(1)c and plasma renin, and negatively with plasma angiotensinogen and body mass index. A multiple regression analysis including these variables resulted in serum ACE activity (p<0.001), ACE genotype (negatively, p<0.001) and HbA(1)c (p=0.023) as explaining variables.CONCLUSIONS/INTERPRETATION: Results suggest that a common factor is involved in the regulation of both plasma SSAO and serum ACE, which is different from the genetic determination of ACE activity.",
keywords = "Amine Oxidase (Copper-Containing), Angiotensin-Converting Enzyme Inhibitors, Body Mass Index, Diabetes Mellitus, Type 1, Diabetic Angiopathies, Diabetic Foot, Diabetic Nephropathies, Diabetic Neuropathies, Diabetic Retinopathy, Hemoglobin A, Glycosylated, Humans, Peptidyl-Dipeptidase A, Journal Article, Research Support, Non-U.S. Gov't",
author = "F Boomsma and U Pedersen-Bjergaard and Birgit Agerholm-Larsen and H Hut and Dhamrait, {Sukhbir S.} and B Thorsteinsson and {van den Meiracker}, {Anton H}",
year = "2005",
month = may,
doi = "10.1007/s00125-005-1716-4",
language = "English",
volume = "48",
pages = "1002--7",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus

AU - Boomsma, F

AU - Pedersen-Bjergaard, U

AU - Agerholm-Larsen, Birgit

AU - Hut, H

AU - Dhamrait, Sukhbir S.

AU - Thorsteinsson, B

AU - van den Meiracker, Anton H

PY - 2005/5

Y1 - 2005/5

N2 - AIMS/HYPOTHESIS: Plasma semicarbazide-sensitive amine oxidase (SSAO) is elevated in patients with type 1 and type 2 diabetes and has been implicated in the pathophysiology of diabetic late complications. The regulation of SSAO production remains unknown. We studied correlations between plasma SSAO activity and parameters associated with diabetic late complications.METHODS: Plasma SSAO was measured in a well-characterised group of 287 patients with type 1 diabetes. Standard statistical methods were used to investigate correlations with clinical parameters and components of the renin-angiotensin system.RESULTS: Overall, plasma SSAO was elevated, at 693+/-196 mU/l (mean+/-SD; normal controls 352+/-102 mU/l). Plasma SSAO was higher in the group with late complications or hypertension, and in patients treated with ACE-inhibitors. In univariate analysis a significant positive correlation (p<0.001, r=0.27) was found between plasma SSAO and serum ACE activity in patients untreated with ACE inhibitors or angiotensin II receptor antagonists (n=221), but plasma SSAO did not differ by ACE I/D genotype. Plasma SSAO correlated positively with duration of diabetes, HbA(1)c and plasma renin, and negatively with plasma angiotensinogen and body mass index. A multiple regression analysis including these variables resulted in serum ACE activity (p<0.001), ACE genotype (negatively, p<0.001) and HbA(1)c (p=0.023) as explaining variables.CONCLUSIONS/INTERPRETATION: Results suggest that a common factor is involved in the regulation of both plasma SSAO and serum ACE, which is different from the genetic determination of ACE activity.

AB - AIMS/HYPOTHESIS: Plasma semicarbazide-sensitive amine oxidase (SSAO) is elevated in patients with type 1 and type 2 diabetes and has been implicated in the pathophysiology of diabetic late complications. The regulation of SSAO production remains unknown. We studied correlations between plasma SSAO activity and parameters associated with diabetic late complications.METHODS: Plasma SSAO was measured in a well-characterised group of 287 patients with type 1 diabetes. Standard statistical methods were used to investigate correlations with clinical parameters and components of the renin-angiotensin system.RESULTS: Overall, plasma SSAO was elevated, at 693+/-196 mU/l (mean+/-SD; normal controls 352+/-102 mU/l). Plasma SSAO was higher in the group with late complications or hypertension, and in patients treated with ACE-inhibitors. In univariate analysis a significant positive correlation (p<0.001, r=0.27) was found between plasma SSAO and serum ACE activity in patients untreated with ACE inhibitors or angiotensin II receptor antagonists (n=221), but plasma SSAO did not differ by ACE I/D genotype. Plasma SSAO correlated positively with duration of diabetes, HbA(1)c and plasma renin, and negatively with plasma angiotensinogen and body mass index. A multiple regression analysis including these variables resulted in serum ACE activity (p<0.001), ACE genotype (negatively, p<0.001) and HbA(1)c (p=0.023) as explaining variables.CONCLUSIONS/INTERPRETATION: Results suggest that a common factor is involved in the regulation of both plasma SSAO and serum ACE, which is different from the genetic determination of ACE activity.

KW - Amine Oxidase (Copper-Containing)

KW - Angiotensin-Converting Enzyme Inhibitors

KW - Body Mass Index

KW - Diabetes Mellitus, Type 1

KW - Diabetic Angiopathies

KW - Diabetic Foot

KW - Diabetic Nephropathies

KW - Diabetic Neuropathies

KW - Diabetic Retinopathy

KW - Hemoglobin A, Glycosylated

KW - Humans

KW - Peptidyl-Dipeptidase A

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1007/s00125-005-1716-4

DO - 10.1007/s00125-005-1716-4

M3 - Journal article

C2 - 15830186

VL - 48

SP - 1002

EP - 1007

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 5

ER -

ID: 51548619